tiprankstipranks
Trending News
More News >
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
US Market

Y-Mabs Therapeutics (YMAB) Income Statement

Compare
510 Followers

Y-Mabs Therapeutics Income Statement

Last quarter (Q4 2024), Y-Mabs Therapeutics's total revenue was $26.50M, an increase of 13.41% from the same quarter last year. In Q4, Y-Mabs Therapeutics's net income was $-6.79M. See Y-Mabs Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 87.69M$ 84.82M$ 65.27M$ 34.90M$ 20.75M
Gross Profit
$ 72.43M$ 73.40M$ 57.70M$ 32.38M$ 18.55M
Operating Expenses
$ 103.64M$ 99.08M$ 152.51M$ 147.82M$ 138.48M
Depreciation and Amortization
$ 0.00$ 735.00K$ 839.00K$ 782.00K$ 396.00K
EBITDA
$ -31.20M$ -24.94M$ -94.73M$ -54.49M$ -119.54M
Operating Income
$ -31.20M$ -25.67M$ -94.81M$ -115.43M$ -119.94M
Other Income/Expenses
$ 1.39M$ 4.81M$ -757.00K$ 60.16M$ 598.00K
Pretax Income
$ -29.81M$ -20.87M$ -95.57M$ -55.27M$ -119.34M
Net Income
$ -29.67M$ -21.43M$ -96.33M$ -56.34M$ -118.34M
Per Share Metrics
Basic EPS
$ -0.67$ -0.49$ -2.20$ -1.30$ -2.95
Diluted EPS
$ -0.67$ -0.49$ -2.20$ -1.30$ -2.95
Weighted Average Shares Outstanding
44.33M 43.65M 43.70M 43.18M 40.12M
Weighted Average Shares Outstanding (Diluted)
44.33M 43.65M 43.70M 43.18M 40.12M
Currency in USD

Y-Mabs Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis